AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 12 min read$NUVL

Noci Darlene sold $164K of NUVL

Noci Darlene (Chief Development Officer) sold 1,500 shares of Nuvalent, Inc. (NUVL) at $109.30 ($0.16M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Noci Darlene
Published Jun 1, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
medium confidence
Mentioned
$NUVL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

The disclosure adds incremental information about insider activity but does not introduce new company fundamentals (no guidance, trial results, or deal terms).

02

Market read

Primarily a sentiment/positioning datapoint for NUVL rather than a catalyst.

03

What to watch

Insider sales can be routine (tax/portfolio rebalancing) and the disclosure date may not align with market reaction; compare with prior Form 4 cadence and total insider net activity.

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-01; sale executed 2026-05-28.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by Nuvalent’s Chief Development Officer under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NUVLNeutralMedium confidence
Context

Nuvalent CDO Noci Darlene sold 1,500 shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-01.

Expected impact

Likely limited/short-lived price impact; any move would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is an ownership-change disclosure with a stated pre-arranged 10b5-1 plan, and it provides no new operating/clinical/financial catalyst.

Market effects

Sector

Minimal; this is company-specific insider activity without sector-wide information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the 10b5-1 plan size is unusually large versus prior patterns, traders may still front-run potential negative sentiment despite the plan.

Key entities

  • issuer
    Nuvalent, Inc.

    Subject of the insider transaction disclosure; CDO sold shares under a 10b5-1 plan.

  • insider
    Noci Darlene

    Chief Development Officer who executed the reported sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NUVL insider trading history →

Related articles

JUL 15
$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

investegate.co.uk4 min
JUN 10
$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

finance.yahoo.com7 min
JUN 9
$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

latimes.com6 min
JUN 9
$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

benzinga.com7 min
JUN 9
$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

rttnews.com6 min
JUN 9
$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.

benzinga.com4 min